A Comparison of Diagnostic Models and Prognostic Scores of ACLF: Towards Global Harmonization
Hu, M.; Luo, J.; Verma, N.; Garg, P.; Taneja, S.; Carbonell-Asins, J. A.; Ballester, M. P.; Qi, T.; Jameie-Oskooei, S.; Cai, Q.; Liang, X.; Li, J.; Wu, T.; Li, J.; Li, P.; Zhou, Q.; Xin, J.; Shi, D.; Jiang, J.; Qiang, W.; Hong, C.; Chen, X.; Zhu, B.; Feng, T.; Zheng, J.; Huang, Y.; Ye, F.; Lin, B.; Chen, J.; Mookerjee, R. P.; Huang, Y.; You, S.; Engelmann, C.; Chen, Y.; Duseja, A.; Li, J.; Jalan, R.
Show abstract
Background and AimsAcute-on-chronic liver failure (ACLF) is associated with high short-term mortality, but substantial heterogeneity among existing diagnostic and prognostic models results in inconsistent patient identification and risk assessment. We conducted a systematic head-to-head comparison of major ACLF diagnostic and prognostic models to evaluate concordance, short-term mortality prediction and clinical utility, with the goal of informing harmonization of ACLF assessment. MethodsWe analysed 3,370 patients with acute decompensation of cirrhosis in the COSSH cohort, with external validation in an independent Ambi-Spective cohort from India (n=2,055). Five ACLF diagnostic models were evaluated for identification of patients at risk of 28-day mortality. Reclassification was assessed using net reclassification improvement. Prognostic scores were compared using concordance index, integrated discrimination improvement, calibration, and decision-curve analysis. ResultsDiagnostic frameworks identified markedly different proportions of ACLF. A-TANGO and COSSH-ACLF classified the largest high-risk populations while maintaining substantial short-term mortality and balanced sensitivity-specificity profiles. Compared with COSSH-ACLF, A-TANGO improved net reclassification by 7.7%, with further gains versus EASL-CLIF (11.8%), APASL-ACLF (36.4%), and NACSELD-ACLF (45.9%). In the external cohort, A-TANGO and COSSH-ACLF showed similar discrimination and identified comparable proportions of patients. Combined application of the two models delineated three clinically meaningful strata, identifying a discordant intermediate-risk group with approximately 11% 28-day mortality. Among prognostic scores, COSSH-ACLF II and A-TANGO OF scores demonstrated strong and complementary performance across cohorts. ConclusionsOutcome-anchored ACLF definitions converge in identifying patients at highest short-term risk across diverse populations. Alignment between A-TANGO and COSSH-ACLF, together with identification of an intermediate-risk phenotype, supports a data-driven framework for improving consistency and advancing global harmonization of ACLF diagnosis and risk stratification.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Breakthrough SARS-CoV-2 Infection Outcomes in Vaccinated Patients with Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study 94%
- Vascular damage and excessive proliferation compromise liver function after extended hepatectomy in mice 92%
- Test-retest reliability of hepatic venous pressure gradient and impact on trial design: a study in 289 patients from the control groups of 20 randomized trials 91%
Similar papers in this journal
- Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: A multicenter cohort study 94%
- Multiple indicators of gut dysbiosis predict all-cause and cause-specific mortality in solid organ transplant recipients 90%
- Residual SARS-CoV-2 viral antigens detected in gastrointestinal and hepatic tissues from two recovered COVID-19 patients 89%
Similar papers in this journal
Similar papers in this journal
- Classification of virologic trajectories during nucleos/tide analogue treatment of hepatitis B virus (HBV) infection 92%
- Liver-specification of human iPSC-derived endothelial cells transplanted into mouse liver 92%
- Abnormal liver tests in admitted patients with SARS-Cov-2 or other respiratory viruses- prognostic similarities and temporal disparities 92%
Similar papers in this journal
- Outcomes of SARS-CoV-2 Infection in Patients with Chronic Liver Disease and Cirrhosis: a N3C Study 96%
- Rifaximin does not increase the rate of 30-day mortality in patients with cirrhosis and daptomycin in two National US-based cohorts 94%
- iPSC-derived hepatocytes from patients with nonalcoholic fatty liver disease display a disease-specific gene expression profile 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.